Oculis Holding AG
OCSDrugs in Pipeline
8
Phase 3 Programs
5
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 1 past
OCS-01
Inflammation Eye Pain
Vehicle
Diabetic Macular Edema
Dexamethasone ophthalmic suspension (OCS-01)
Diabetic Macular Edema
licaminlimab
Dry Eye Disease
Privosegtor
Optic Neuritis
OCS-05 +SoC (corticosteroid) IV administration
Optic Neuritis
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
Inflammation Corneal
Dexamethasone nanoparticles eye drops
Diabetic Macular Edema
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
OCS-01 | Phase 3 | Inflammation Eye Pain | - | - |
Vehicle | Phase 3 | Diabetic Macular Edema | - | - |
Dexamethasone ophthalmic suspension (OCS-01) | Phase 3 | Diabetic Macular Edema | - | - |
licaminlimab | Phase 3 | Dry Eye Disease | - | - |
Privosegtor | Phase 3 | Optic Neuritis | - | - |
OCS-05 +SoC (corticosteroid) IV administration | Phase 2 | Optic Neuritis | - | - |
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL | Phase 2 | Inflammation Corneal | - | - |
Dexamethasone nanoparticles eye drops | Phase 2 | Diabetic Macular Edema | - | - |